Sarepta Therapeutics (SRPT) News Today $37.72 -0.89 (-2.31%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$37.55 -0.17 (-0.45%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Q2 Earnings Forecast for SRPT Issued By Zacks ResearchSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Research analysts at Zacks Research issued their Q2 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Monday, May 26th. Zacks Research analyst S. Ganoria forecMay 30 at 7:51 AM | marketbeat.comResearch Analysts Set Expectations for SRPT Q2 EarningsMay 30 at 1:18 AM | americanbankingnews.comD. E. Shaw & Co. Inc. Sells 11,389,239 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)D. E. Shaw & Co. Inc. lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 100.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,500 shares of the biotechnology company's stock afMay 28 at 3:25 AM | marketbeat.comWas Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?May 27, 2025 | insidermonkey.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $36.39 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 299,30May 27, 2025 | marketbeat.comTwo Sigma Investments LP Has $9.13 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Two Sigma Investments LP lessened its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 62.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,054 shares of tMay 27, 2025 | marketbeat.com46,986 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Purchased by Woodline Partners LPWoodline Partners LP purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 46,986 shares of the biotechnology company's stock, valuedMay 26, 2025 | marketbeat.comHC Wainwright Reaffirms "Neutral" Rating for Sarepta Therapeutics (NASDAQ:SRPT)May 25, 2025 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Receives "Neutral" Rating from HC WainwrightHC Wainwright reissued a "neutral" rating and issued a $40.00 target price on shares of Sarepta Therapeutics in a report on Thursday.May 24, 2025 | marketbeat.comSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23, 2025 | benzinga.comSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23, 2025 | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up - Still a Buy?Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up - What's Next?May 23, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $84.00May 23, 2025 | americanbankingnews.comSarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study ContinueMay 21, 2025 | marketwatch.comSarepta, Roche get U.K. feedback to lift clinical hold on Elevidys' Duchenne trialMay 21, 2025 | msn.comSarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in DuchenneMay 21, 2025 | finance.yahoo.comSarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular DystrophyMay 21, 2025 | businesswire.comVestal Point Capital LP Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Vestal Point Capital LP acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 250,000 shares of the biotechnology company'sMay 21, 2025 | marketbeat.comTriglav Skladi D.O.O. Invests $1.34 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Triglav Skladi D.O.O. purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,000 shares of the biotechnologMay 21, 2025 | marketbeat.comNuveen Asset Management LLC Increases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Nuveen Asset Management LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 10.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 524,579 shares of the biotechnology company's sMay 21, 2025 | marketbeat.comSarepta Shares Higher After J.P. Morgan NoteMay 20, 2025 | marketwatch.comSRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative DelaysMay 20, 2025 | msn.comSummit Partners Public Asset Management LLC Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Summit Partners Public Asset Management LLC increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 174.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 379,150 sMay 19, 2025 | marketbeat.comSuvretta Capital Management LLC Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Suvretta Capital Management LLC acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 17,888 shares of the biotechnologyMay 19, 2025 | marketbeat.comRafferty Asset Management LLC Sells 28,806 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Rafferty Asset Management LLC lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 20.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 109,236 shares of the biotechnology compMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Has $12.03 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Sphera Funds Management LTD. lessened its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 22.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 98,921 shares oMay 18, 2025 | marketbeat.comSarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of TreatmentMay 16, 2025 | finance.yahoo.comOrbimed Advisors LLC Sells 41,100 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Orbimed Advisors LLC lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 4.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 963,400 shares of the biotechnology company's stoMay 15, 2025 | marketbeat.comBearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimatesMay 14, 2025 | finance.yahoo.comPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore (SRPT)These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and nextMay 14, 2025 | marketbeat.comEnsign Peak Advisors Inc Has $21.10 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Ensign Peak Advisors Inc cut its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 23.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 173,491 shares of the bMay 14, 2025 | marketbeat.comSarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular DystrophyMay 13, 2025 | finance.yahoo.comJ. Goldman & Co LP Purchases 8,628 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)J. Goldman & Co LP lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 10.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 87,866 shares of the biotechnology company's stock afterMay 13, 2025 | marketbeat.comJanus Henderson Group PLC Sells 30,188 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Janus Henderson Group PLC decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 0.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,328,323 shares of the biotMay 13, 2025 | marketbeat.com2 Stocks Near Their 52-Week Lows That Still Aren't Worth BuyingMay 13, 2025 | fool.comSarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside PotentialMay 12, 2025 | finance.yahoo.comSarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside PotentialMay 11, 2025 | insidermonkey.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Holdings Lifted by Farallon Capital Management LLCFarallon Capital Management LLC increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,865,100 shares of the biMay 11, 2025 | marketbeat.comBokf Na Acquires 11,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Bokf Na boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 599,500.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,992 shares of the biotechnology company's stock after acqMay 11, 2025 | marketbeat.comStifel Financial Corp Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Stifel Financial Corp lessened its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 72.9% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,069 shares of the biotechnology company's stock after seMay 11, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Evercore ISIEvercore ISI downgraded Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price objective for the company. in a research report on Thursday.May 10, 2025 | marketbeat.comFred Alger Management LLC Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Fred Alger Management LLC lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 269,112 shares of the biotechnoMay 10, 2025 | marketbeat.comBalyasny Asset Management L.P. Sells 218,359 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Balyasny Asset Management L.P. lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 56.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 165,973 shares of the biotechnology coMay 10, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT). In a filing disclosed on May 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Sarepta Therapeutics stock on April 14th. The trade occurred inMay 10, 2025 | marketbeat.comIs Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?May 10, 2025 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $81.00 at Cantor FitzgeraldCantor Fitzgerald decreased their price objective on Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating for the company in a research report on Wednesday.May 9, 2025 | marketbeat.comOppenheimer Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $123.00Oppenheimer dropped their price objective on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a research note on Wednesday.May 9, 2025 | marketbeat.comPiper Sandler Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock PricePiper Sandler reduced their price objective on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday.May 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTMay 9, 2025 | globenewswire.comMorgan Stanley Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceMorgan Stanley decreased their target price on Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a research report on Wednesday.May 9, 2025 | marketbeat.com Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼0.750.87▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼1314▲SRPT Articles Average Week Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Moderna News Today Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Roivant Sciences News Today Revolution Medicines News Today Blueprint Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRPT Stock Free SRPT Stock Alerts